Cited by

• Structures 4-n-propyl Piperazines as Non-Imidazole Histamine H3 Antagonists.

  Olczak A, Sukiennik J, Olszewska B, Stefaniak M, Walczyński K, Szczesio M. Olczak A, et al. Materials (Basel). 2021 Nov 22;14(22):7094. doi: 10.3390/ma14227094. Materials (Basel). 2021. PMID: 34832494 Free PMC article.
• Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.

  Kozyra P, Pitucha M. Kozyra P, et al. Int J Mol Sci. 2022 Aug 9;23(16):8874. doi: 10.3390/ijms23168874. Int J Mol Sci. 2022. PMID: 36012142 Free PMC article. Review.
• Non-Imidazole Histamine H₃ Ligands. Part VII. Synthesis, In Vitro and In Vivo Characterization of 5-Substituted-2-thiazol-4-n-propylpiperazines.

  Guryn R, Staszewski M, Stasiak A, McNaught Flores D, Fogel WA, Leurs R, Walczyński K. Guryn R, et al. Molecules. 2018 Feb 3;23(2):326. doi: 10.3390/molecules23020326. Molecules. 2018. PMID: 29401659 Free PMC article.
• Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

  Darras FH, Pockes S, Huang G, Wehle S, Strasser A, Wittmann HJ, Nimczick M, Sotriffer CA, Decker M. Darras FH, et al. ACS Chem Neurosci. 2014 Mar 19;5(3):225-42. doi: 10.1021/cn4002126. Epub 2014 Jan 14. ACS Chem Neurosci. 2014. PMID: 24422467 Free PMC article.
• Identification of Histamine H₃ Receptor Ligands Using a New Crystal Structure Fragment-based Method.

  Frandsen IO, Boesgaard MW, Fidom K, Hauser AS, Isberg V, Bräuner-Osborne H, Wellendorph P, Gloriam DE. Frandsen IO, et al. Sci Rep. 2017 Jul 6;7(1):4829. doi: 10.1038/s41598-017-05058-w. Sci Rep. 2017. PMID: 28684785 Free PMC article.